Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01927341 |
| Title | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | NLD | ITA | FRA | ESP | CAN | BEL |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of California at Los Angeles Dept of Onc | Los Angeles | California | 90095 | United States | Details | |
| Memorial Sloan Kettering Cancer Center Oncology Dept | New York | New York | 90033 | United States | Details | |
| Pfizer Investigative Site | Leuven | 3000 | Belgium | Details | ||
| Pfizer Investigative Site | Toronto | Ontario | M5G 2M9 | Canada | Details | |
| Pfizer Investigative Site | Toulouse Cedex 9 | 31059 | France | Details | ||
| Pfizer Investigative Site | Milano | MI | 20162 | Italy | Details | |
| Pfizer Investigative Site | Amsterdam | 1066 CX | Netherlands | Details | ||
| Pfizer Investigative Site | Barcelona | Catalunya | 08035 | Spain | Details |